Stock fact sheet · data as of
Nephros, Inc. (NEPH): fair value, margin of safety and Wheel Score
Healthcare · Medical - Instruments & Supplies · United States · High Growth
Is NEPH undervalued?
NEPH has a margin of safety of 34%: the stock closed at 3.51 on 16 Oct 2026 against a GLS average fair value of 5.34. 3 of the 5 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
There is a wide gap between EPV (1.78) and GLS Growth (9.79). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files NEPH under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for NEPH
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 1.99 | -43% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 9.15 | +161% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 4.00 | +14% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 9.79 | +179% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 1.78 | -49% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.7168 | -80% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 4.00 | +14% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Nephros, Inc. scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 3.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are moderate - ROIC 10.6%, ROE 11.7%, ROA 8.8% - with debt at 0.10 times equity and negative free cash flow.
Nephros, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 100% (quarter Q2 FY2026).
Institutional ownership scores 6/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | 10.6% |
|---|---|---|---|
| GLS Moat | 3.5 / 10 | ROE | 11.7% |
| Debt / equity | 0.10 | ROA | 8.8% |
| Free-cash-flow yield | -1.7% | Payout ratio | 0% |
| Institutions | 6 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 39: No options
No options are listed on Nephros, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 26k shares a day on a market cap of $38M, with a beta of 1.64 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 5 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 34% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 5 / 15 | moat 3.5/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 5 / 20 | 26k shares/day, $38M cap, beta 1.64 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026 (after the close), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Instruments & Supplies
The 12 companies below are the closest to Nephros, Inc. by market cap within the Medical - Instruments & Supplies industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| HBIO Harvard Bioscience, Inc. | 8.31 | - | - | 32No options | $38M |
| POCI Precision Optics Corporation, Inc. | 4.41 | - | - | 31No options | $48M |
| MLSS Milestone Scientific Inc. | 0.3267 | - | - | 32Weak | $30M |
| DXR Daxor Corporation | 10.20 | 42.03 | +76% | 39No options | $60M |
| RVP Retractable Technologies, Inc. | 0.5931 | 0.7365 | +19% | 37Weak | $18M |
| BNGO Bionano Genomics, Inc. | 1.37 | - | - | 26No options | $16M |
| ZJYL Jin Medical International Ltd. | 2.02 | 1.68 | -20% | 17No options | $16M |
| FEMY Femasys Inc. | 1.74 | - | - | 24No options | $15M |
| STXS Stereotaxis, Inc. | 1.05 | - | - | 36Weak | $105M |
| KRMD KORU Medical Systems, Inc. | 3.03 | 0.2707 | -1019% | 28Weak | $139M |
| NNNN Anbio Biotechnology Class A Ordinary Shares | 3.30 | 5.39 | +39% | 39No options | $145M |
| PDEX Pro-Dex, Inc. | 59.82 | 87.22 | +31% | 39No options | $193M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about NEPH
Is NEPH undervalued right now?
By the GLS models, yes: at 3.51 the stock is 34% below the average fair value of 5.34 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of NEPH and what does it mean?
NEPH has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for NEPH?
5.34 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Nephros, Inc. report earnings next?
The next earnings report is due on 5 Nov 2026 (after the close), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does NEPH have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on NEPH, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.